Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Summary

This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to standard chemotherapy or not eligible to standard chemotherapy can be included. Patients will be treated with 400 mg Nilotinib bid (total daily dose 800 mg). RAD001 will be added after a treatment duration of 1 week in a dosage of 2,5 mg/day. Treatment duration will be 25 weeks.

Timeline

Start

2007-12

Primary completion

2012-06

Completion

—

Drugs

Indications